Hepatitis D - Pipeline Insight, 2026

DelveInsight's, "Hepatitis D - Pipeline Insight, 2026" report provides comprehensive insights about 15+ companies and 18+ pipeline drugs in Hepatitis D pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered:

• Global coverage

Hepatitis D: Understanding

Hepatitis D: Overview

Hepatitis D virus (HDV) is a unique, defective RNA virus that depends entirely on HBV for its replication and transmission. Known as the delta agent, HDV uses the hepatitis B surface antigen (HBsAg) from HBV to form its outer envelope, making it capable of infecting only individuals who are also infected with HBV. Structurally simple, HDV carries a small, circular RNA genome and encodes only the hepatitis D antigen (HDAg), relying heavily on host cellular machinery for replication. Interestingly, HDV infection often suppresses HBV replication through mechanisms that are not yet fully understood. HDV can manifest either as a co-infection with HBV, which usually results in an acute and self-limiting disease, or as a superinfection in individuals with chronic HBV, which typically leads to more severe outcomes. Co-infection with HDV is associated with accelerated liver damage, a higher likelihood of cirrhosis, and an increased risk of liver failure and hepatocellular carcinoma compared to HBV infection alone, making it the most severe form of viral hepatitis.

Hepatitis D infection can present with a broad spectrum of symptoms, many of which overlap with those seen in other forms of viral hepatitis. Early signs often include non-specific symptoms such as fever, fatigue, loss of appetite, nausea, and vomiting, which can be mistaken for a general viral illness. As the infection progresses, more liver-specific signs may appear, such as dark urine, pale-colored stools, and jaundice-the yellowing of the skin and eyes-indicative of impaired liver function and elevated bilirubin levels. Some patients may also report abdominal discomfort or pain, particularly in the upper right quadrant, along with joint pain. In severe or advanced cases, complications like confusion, spontaneous bruising, or bleeding may emerge, signaling worsening liver function or potential liver failure. The severity of symptoms can vary greatly depending on whether the infection is acute or chronic and whether it occurs as a co-infection or superinfection with hepatitis B.

Hepatitis D virus (HDV) is a defective RNA virus that relies on hepatitis B virus (HBV) for replication and uses HBV surface proteins to form its outer envelope. It encodes only the hepatitis D antigen (HDAg), with two forms: a short one that supports replication and a long one that facilitates viral assembly. HDV infects only individuals already carrying HBV and can present as either an acute coinfection or a more severe superinfection, the latter often leading to chronic liver disease. Liver damage is mainly driven by the host immune response, with disease severity influenced by HDV genotype-genotype 1 being the most common and aggressive.

Treatment options for hepatitis D virus (HDV) remain limited, particularly for acute infection, for which no approved therapies exist. For chronic HDV, pegylated interferon alpha is the preferred option, though it is not FDA-approved, and its effectiveness varies. It is usually given once weekly for a year or more, with the goal of suppressing viral replication and reducing liver inflammation. Success is measured by the clearance of HDV RNA from the blood and improvement in liver enzyme levels. In advanced cases progressing to cirrhosis, liver transplantation becomes the only viable treatment.

"Hepatitis D- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis D pipeline landscape is provided which includes the disease overview and Hepatitis D treatment guidelines. The assessment part of the report embraces, in depth Hepatitis D commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis D collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights:

• The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis D R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis D.

Hepatitis D Emerging Drugs Chapters

This segment of the Hepatitis D report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis D Emerging Drugs

• Brelovitug: Mirium Pharmaceuticals

Brelovitug is an investigational, highly potent, pan-genotypic, fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets the surface antigen (anti-HBsAg) on the chronic hepatitis delta virus (HDV). Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles. Brelovitug has FDA Breakthrough Therapy designation for the treatment of chronic HDV infection and PRIME and Orphan designations from the European Medicines Agency. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Hepatitis D infections.

• GS-4321: Gilead Sciences

GS-4321 is an investigational hepatitis delta virus (HDV) pre-S1 neutralizing antibody (nAb) being developed by Gilead Sciences for the treatment of chronic hepatitis delta (CHD). GS-4321 is an HDV pre-S1 nAb, and its ongoing clinical study is evaluating the safety, tolerability, pharmacokinetics, and antiviral activity of the drug in healthy participants and individuals with chronic hepatitis delta. The Phase I/II study is currently recruiting and is designed to assess escalating single doses in healthy participants in Phase I, followed by multiple escalating doses in participants with CHD in Phase II to evaluate efficacy and safety. GS-4321 is administered as a solution for injection. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Hepatitis D.

Hepatitis D: Therapeutic Assessment

This segment of the report provides insights about the different Hepatitis D drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Hepatitis D

There are approx. 15+ key companies which are developing the therapies Hepatitis D. The companies which have their Hepatitis D drug candidates in the most advanced stage, i.e. Phase III include, Mirium Pharmaceuticals and others.

• Phases

DelveInsight's report covers around 18+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis D: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis D therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis D drugs.

Hepatitis D Report Insights

• Hepatitis D Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Hepatitis D Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions:

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Hepatitis D drugs?
• How many Hepatitis D drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis D?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hepatitis D therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hepatitis D and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mirium Pharmaceuticals
• Gilead Sciences
• Assembly Biosciences
• Model Medicines

Key Products

• Brelovitug
• GS-4321
• ABI-6250
• MDL-001